- Home
- AKBA vs ORIC Comparison
AKBA vs ORIC Comparison
Compare AKBA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ORIC
- Stock Information
- Founded
- AKBA 2007
- ORIC 2014
- Country
- AKBA United States
- ORIC United States
- Employees
- AKBA N/A
- ORIC N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- AKBA Health Care
- ORIC Health Care
- Exchange
- AKBA Nasdaq
- ORIC Nasdaq
- Market Cap
- AKBA 861.7M
- ORIC 974.1M
- IPO Year
- AKBA 2014
- ORIC 2020
- Fundamental
- Price
- AKBA $2.85
- ORIC $10.81
- Analyst Decision
- AKBA Strong Buy
- ORIC Strong Buy
- Analyst Count
- AKBA 5
- ORIC 10
- Target Price
- AKBA $6.90
- ORIC $17.33
- AVG Volume (30 Days)
- AKBA 3.6M
- ORIC 903.1K
- Earning Date
- AKBA 11-06-2025
- ORIC 11-11-2025
- Dividend Yield
- AKBA N/A
- ORIC N/A
- EPS Growth
- AKBA N/A
- ORIC N/A
- EPS
- AKBA N/A
- ORIC N/A
- Revenue
- AKBA $203,733,000.00
- ORIC N/A
- Revenue This Year
- AKBA $43.91
- ORIC N/A
- Revenue Next Year
- AKBA $32.09
- ORIC N/A
- P/E Ratio
- AKBA N/A
- ORIC N/A
- Revenue Growth
- AKBA 16.75
- ORIC N/A
- 52 Week Low
- AKBA $1.24
- ORIC $3.90
- 52 Week High
- AKBA $4.08
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- AKBA 38.07
- ORIC 51.83
- Support Level
- AKBA $2.91
- ORIC $10.37
- Resistance Level
- AKBA $3.02
- ORIC $11.16
- Average True Range (ATR)
- AKBA 0.13
- ORIC 0.53
- MACD
- AKBA -0.00
- ORIC 0.03
- Stochastic Oscillator
- AKBA 11.90
- ORIC 46.43
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.